Key result
Vorapaxar exposure was modestly increased by concomitant food (AUC +43%) and older age (AUC +41%), and decreased by antacid (AUC -15%), which are not expected to affect safety or efficacy.
Why the study?
Does food, antacid, or age affect the pharmacokinetics of single-dose vorapaxar 40 mg in healthy volunteers?
RCT (n=101)
Open-label
parallel group
Does food, antacid, or age affect the pharmacokinetics of single-dose vorapaxar 40 mg in healthy volunteers?
Food, antacid, and older age cause modest changes in vorapaxar exposure that are not expected to affect safety or efficacy.
No dose adjustment needed for food, antacid, or age with vorapaxar; extends single-dose PK data in healthy volunteers.
This randomized, open-label, parallel group study examined the effects of food, antacid, and age on the pharmacokinetics of vorapaxar. In total, 101 subjects were enrolled including 83 young adults (18-45 years) and 18 elderly subjects (>65 years). Subjects received single-dose vorapaxar 40 mg after a 10-hour fast (young and elderly) or with extra-strength antacid, food, or 1 or 2 hours after food (young only). Vorapaxar 40 mg was rapidly absorbed after a fast (median Tmax : 1 hour). Administration with food or 1 or 2 hours post-meal modestly increased vorapaxar mean area under the curve (AUC) and Cmax and prolonged median Tmax by 1 hour. Concomitant food modestly increased vorapaxar AUC from time zero to infinity [AUC(I)] and Cmax 43% and 31%, respectively. Antacid modestly decreased vorapaxar AUC(I) by 15% and Cmax by 38%, and increased median Tmax by 1 hour. Vorapaxar AUC(I) and Cmax were 41% and 29% higher, respectively, in elderly versus young subjects. Concomitant food and older age were associated with modest increases, and antacid was associated with a small decrease in vorapaxar exposure, which are not expected to affect the drug's safety or efficacy.
No takes yet. Share an insight, caveat, or question.
Kosoglou et al. (2013) conducted an RCT in Healthy Volunteers (n=101). Vorapaxar vs. Fasting state and young adults was evaluated on Pharmacokinetics (AUC, Cmax, Tmax). Vorapaxar exposure was modestly increased by concomitant food (AUC +43%) and older age (AUC +41%), and decreased by antacid (AUC -15%), which are not expected to affect safety or efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: